A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer

Rutherford, Thomas J.; Orr, James W.; Grendys, Edward C.; Edwards, Robert P.; Krivak, Thomas C.; Holloway, Robert W.; Moore, Richard G.; Puls, Larry E.; Tillmanns, Todd; Schink, Julian C.; Brower, Stacey L.; Tian, Chunqiao; Herzog, Thomas J.

doi:10.1016/j.ygyno.2013.08.009

Cited by 44 publications

(51 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, our PFS data revealed significantly worse outcome in women with Type II EOC with resistant compared to non-resistant chemoresponse assay results for carboplatin, which is concordant with the original study results and the published literature [14,15]. The relationship of PFS with chemoresponse assay results was also suggested in the Type I EOC cohort and supports the clinical validity of the assay in women with Type I EOC.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis

Previs

Leath

Coleman

et al. 2015

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

“…Details regarding the chemoresponse assay employed in this study (ChemoFx®, Helomics Corporation, Pittsburgh, PA) have been described elsewhere [14,15]. Briefly, the assay preparation included an immunocytochemistry step, using cytokeratin and vimentin antibodies to confirm that the cells were epithelial and not stromal cell types.…”

Section: Chemoresponse Assaymentioning

confidence: 99%

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis

Previs

Leath

Coleman

et al. 2015

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

“…Assay-PFS association was consistent in both platinum-sensitive and platinum-resistant tumors (HR: 0.71 and 0.66, respectively) and was independent of other covariates (HR = 0.66, 95 % CI 0.47–0.94, p = 0.020). Moreover, the results indicated that more than 50 % of the patients had at least one S therapy identified by the assay, whereas only 25 % of them were empirically treated with an S drug, suggesting that the number of patients potentially experiencing improved OS may more than double when physicians reference the assay [49]. …”

Section: Chemofxmentioning

confidence: 99%

Overview of a chemoresponse assay in ovarian cancer

Grendys

Fiorica²,

Orr

et al. 2014

Clin Transl Oncol

View full text Add to dashboard Cite

The objective of this review is to summarize recent scientific and medical literature regarding chemoresponse assays or chemotherapy sensitivity and resistance assays (CSRAs), specifically as applied to epithelial ovarian cancer. A total of sixty-seven articles, identified through PubMed using the key words “in vitro chemoresponse assay,” “chemo sensitivity resistance assay,” “ATP,” “HDRA,” “EDR,” “MiCK,” and “ChemoFx,” were reviewed. Recent publications on marker validation, including relevant clinical trial designs, were also included. Recent CSRA research and clinical studies are outlined in this review. Published findings demonstrate benefits regarding patient outcome with respect to recent CSRAs. Specifically, analytical and clinical validations, as well as clinical utility and economic benefit, of the most common clinically used CSRA in the United States support its use to aid in making effective, individualized clinical treatment selections for patients with ovarian cancer.

show abstract

“…In a study from USA with 262 patients, all the patients were treated empirically, but a chemosensitivity assay was also performed concomitantly for all. In addition, in the subgroup of patients treated with assay-sensitive agents, progression-free survival (PFS) and OS are found to be improved, and further analysis has confirmed these results (14,15). Recently, an observational study has also evaluated chemosensitivity profiles of type 1 and type 2 epithelial ovarian cancer (EOC) (16).…”

Section: Discussionmentioning

confidence: 93%

In vitro chemosensitivity in ovarian carcinoma: Comparison of three leading assays

Tatar

Boyraz

Selçuk

et al. 2016

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Material and Methods:Fresh tumoral tissue samples of 26 newly diagnosed primary ovarian cancer patients were studied with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolyum bromide (MTT) assay, adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) and differential staining cytotoxicity (DISC) assays. Chemosensitivity of tumors were studied for paclitaxel, carboplatin, docetaxel, topotecan, gemcitabine, and doxorubicin with each of the three assays. Subgroup analysis was performed for stage, grade, and histologic type. Results:The in vitro chemosensitivity results of MTT, ATP, and DISC assays were found to be similar. The subgroups in which in vitro assays would be more useful were encountered for patients with advanced stage and serous histology ovarian carcinoma. Conclusions:In vitro chemosensitivity can be determined in ovarian carcinoma with ATP, MTT, or DISC assays before the initiation of chemotherapy. These three assays correlate well with each other and are particularly useful for serous and advanced cancers. Large prospective studies comparing standard versus assay-directed therapy with an endpoint of overall survival are required before routine clinical utilization of these assays. (J Turk Ger Gynecol Assoc 2016; 17: 35-40) Keywords: Ovarian cancer, in vitro chemosensitivity, ATP, MTT, DISC Received: 20 January, 2016 Accepted: 22 January, 2016 In vitro chemosensitivity in ovarian carcinoma:Comparison of three leading assays Black and Speer in 1950s (9). The chemosensitivity tests allow detecting the cytotoxic, cytostatic, and apoptotic effects of the chemotherapeutic agent outside the organism. Such an approach is particularly thought to prevent the harmful toxic effects of these agents. Many molecular and cellular assays have been developed to date for the in vitro detection of chemosensitivity. The molecular methods detect the chemosensitivity at the protein or gene level (10,11). Although a single gene may be sufficient for the evaluation, a cytotoxic drug sometimes generates an excessive cellular response (12, 13). Cellular methods provide the efficacy results for multiple drugs simultaneously. Several tests based on cellular methods, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolyum bromide (MTT) chemosensitivity assay, adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA), and differential staining cytotoxicity (DISC) assays, have been described in the literature. Despite the logic that any method that predicts the chemosensitivity of a tumor for an individual patient would be helpful for better regimens, no chemosensitivity assay has achieved widespread clinical use to date. In a study from USA with 262 patients, all the patients were treated empirically, but a chemosensitivity assay was also performed concomitantly for all. In addition, in the subgroup of patients treated with assay-sensitive agents, progression-free survival (PFS) and OS are found to be improved, and further analysis has confirmed these results (14,15). Recently, an observational study h...

show abstract

A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer

Abstract: This prospective study demonstrated improved PFS and OS for patients with either platinum-sensitive or platinum-resistant recurrent ovarian cancer treated with assay-sensitive agents.

Cited by 44 publications

References 26 publications

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis

Overview of a chemoresponse assay in ovarian cancer

In vitro chemosensitivity in ovarian carcinoma: Comparison of three leading assays

Contact Info

Product

Resources

About